Effect of telmisartan on hypertensive dementia patients: an observational study

Abstract

Background: This was a prospective observational study done to observe the effects of telmisartan on cognitive function in hypertensive dementia patients.Methods: The study included new diagnosed hypertensive and normotensive dementia patients. Patients comprised of four groups; hypertensive dementia patients taking telmisartan (group 1), hypertensive dementia patients taking donepezil and telmisartan (group 2), normotensive dementia patients taking donepezil (group 3) and normotensive dementia patients taking drugs which does not affect memory (group 4).Cognitive function of four groups were compared to each other at 4, 8 and 12 weeks.Results: In group 1, 2 and 3 mini-mental state examination (MMSE) scores has increased by 1.69, 16.81, and 13.28 percent and in group 4 there is decrease in MMSE score by 6.03 percent in 12 weeks.Conclusions: In this study we can conclude that telmisartan has dementia preventing propensity which is better than placebo but not as good as donepezil.

Angiotensin II Receptor Blockers in the Management of Hypertension in Preventing Cognitive Impairment and Dementia—A Systematic Review

“…Keshri et al performed a prospective observational trial study to examine the effects of telmisartan on cognitive function in patients with hypertension and dementia [ 48 ]. This study found that while telmisartan is better at preventing dementia than a placebo, it is not better than donepezil [ 48 ].…”

“…Keshri et al performed a prospective observational trial study to examine the effects of telmisartan on cognitive function in patients with hypertension and dementia [ 48 ]. This study found that while telmisartan is better at preventing dementia than a placebo, it is not better than donepezil [ 48 ]. However, when used together, telmisartan and donepezil performed better in terms of MMSE scores, with telmisartan functioning as a potentiator [ 48 ].…”

“…This study found that while telmisartan is better at preventing dementia than a placebo, it is not better than donepezil [ 48 ]. However, when used together, telmisartan and donepezil performed better in terms of MMSE scores, with telmisartan functioning as a potentiator [ 48 ]. Furthermore, Ho et al observed lower levels of white matter hyperintensities (WMH) volume and better memory performance in patients using BBB-crossing ARBs such as losartan [ 49 ].…”

Development of Telmisartan Nanocrystal-Based Dissolving Microneedle for Brain Targeting via Trigeminal Pathway: A Potentially Promising Treatment for Alzheimer’s with an Improved Pharmacokinetic Profile

“…Additionally, animal modeling of TMN demonstrated that its PPAR activity could reduce cognitive decline by regulating neurotrophic factors originating from the brain. 3,8,9 Therefore, TMN could become the first-line therapy for ALZ, replacing ChEI drugs.…”

“…Compared with other ARB medications, TMN was anticipated to have promising therapeutic benefits for persons with type 2 diabetes (T2D) and cardiovascular illnesses as a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR). Additionally, animal modeling of TMN demonstrated that its PPAR activity could reduce cognitive decline by regulating neurotrophic factors originating from the brain. ,, Therefore, TMN could become the first-line therapy for ALZ, replacing ChEI drugs.…”